Seres Therapeutics, Inc.Seres Therapeutics, Inc.Seres Therapeutics, Inc.

Seres Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪185.52 M‬USD
−0.60USD
‪−113.72 M‬USD
‪126.33 M‬USD
‪119.86 M‬
Beta (1Y)
1.85

About Seres Therapeutics, Inc.

CEO
Eric D. Shaff
Headquarters
Cambridge
Employees (FY)
233
Founded
2010
FIGI
BBG0099X6859
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of MCRB is 1.23 USD — it hasn't changed in the past 24 hours. Watch Seres Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Seres Therapeutics, Inc. stocks are traded under the ticker MCRB.
MCRB stock has risen by 16.67% compared to the previous week, the month change is a 62.36% rise, over the last year Seres Therapeutics, Inc. has showed a 73.19% decrease.
We've gathered analysts' opinions on Seres Therapeutics, Inc. future price: according to them, MCRB price has a max estimate of 10.00 USD and a min estimate of 1.00 USD. Watch MCRB chart and read a more detailed Seres Therapeutics, Inc. stock forecast: see what analysts think of Seres Therapeutics, Inc. and suggest that you do with its stocks.
MCRB reached its all-time high on Sep 9, 2015 with the price of 52.00 USD, and its all-time low was 0.54 USD and was reached on Apr 19, 2024. View more price dynamics on MCRB chart.
See other stocks reaching their highest and lowest prices.
MCRB stock is 5.81% volatile and has beta coefficient of 1.85. Track Seres Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Seres Therapeutics, Inc. there?
Today Seres Therapeutics, Inc. has the market capitalization of ‪185.52 M‬, it has increased by 21.51% over the last week.
Yes, you can track Seres Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Seres Therapeutics, Inc. is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
MCRB earnings for the last quarter are −0.27 USD per share, whereas the estimation was −0.34 USD resulting in a 20.98% surprise. The estimated earnings for the next quarter are −0.27 USD per share. See more details about Seres Therapeutics, Inc. earnings.
Seres Therapeutics, Inc. revenue for the last quarter amounts to 0 USD, despite the estimated figure of ‪250.00 K‬ USD. In the next quarter, revenue is expected to reach ‪−263.83 K‬ USD.
MCRB net income for the last quarter is ‪−40.13 M‬ USD, while the quarter before that showed ‪−41.25 M‬ USD of net income which accounts for 2.70% change. Track more Seres Therapeutics, Inc. financial stats to get the full picture.
No, MCRB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 22, 2024, the company has 233.00 employees. See our rating of the largest employees — is Seres Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Seres Therapeutics, Inc. EBITDA is ‪−64.28 M‬ USD, and current EBITDA margin is −72.96%. See more stats in Seres Therapeutics, Inc. financial statements.
Like other stocks, MCRB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Seres Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Seres Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Seres Therapeutics, Inc. stock shows the sell signal. See more of Seres Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.